Seema R. Lalani

Seema R. Lalani

Auto-generated profile, based on publicly available information

Seema R. Lalani


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in JAMA Pediatrics
Verified
Journal Article
Closed access
PDF file
LMLinyan Meng
Linyan Meng
MPMohan Pammi
Mohan Pammi
ASAnirudh Saronwala
Anirudh Saronwala
PMPilar Magoulas
Pilar Magoulas
AGAndrew Ray Ghazi
Andrew Ray Ghazi
SLSeema R. Lalani
Seema R. Lalani
Congenital malformations are estimated to be present in 13% of all admissions to neonatal intensive care units (NICUs) in developed countries1,2 and remain the leading cause of neonatal mortality (estimated at 20%-34%).3,4 While cytogenetic abnormalities5 and copy number variants (CNVs)6 are known causes of birth defects in seriously ill neonates, single-gene disorders are also significant contributors.7-11 The diagnostic tests for the clinical evaluation of newborns with suspected genetic diseases have expanded exponentially in recent years, particularly with the institution of next-generation sequencing (NGS). As the overall burden of genetic disorders in neonates is being explored via implementation of genome-wide sequencing in newborn screening programs,12-14 clinical geneticists and neonatologists are in a unique position to initiate evidence-based studies in large tertiary care centers, deliver care that combines state-of-the-art diagnostic tools and genetic counseling, and provide reproductive options regarding serious genetic diseases in at-risk families.

1 February 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SLSeema R. Lalani
Seema R. Lalani
PLPengfei Liu
Pengfei Liu
JRJill A. Rosenfeld
Jill A. Rosenfeld
LWLevi B. Watkin
Levi B. Watkin
TCTheodore Chiang
Theodore Chiang
YYYaping Yang
Yaping Yang

1 February 2005 in Archives of Neurology
Verified
Journal Article
Open access
PDF file
SLSeema R. Lalani
Seema R. Lalani
GVGeorgirene D. Vladutiu
Georgirene D. Vladutiu
KPKatie Plunkett
Katie Plunkett
TLTimothy E. Lotze
Timothy E. Lotze
AAAdekunle M. Adesina
Adekunle M. Adesina
FSFernando Scaglia
Fernando Scaglia
Background Primary coenzyme Q10(CoQ10) deficiency is rare. The encephalomyopathic form, described in few families, is characterized by exercise intolerance, recurrent myoglobinuria, developmental delay, ataxia, and seizures. Objective To report a rare manifestation of CoQ10deficiency with isolated mitochondrial myopathy without central nervous system involvement. Methods The patient was evaluated for progressive muscle weakness. Comprehensive clinical evaluation and muscle biopsy were performed for histopathologic analysis and mitochondrial DNA and respiratory chain enzyme studies. The patient began taking 150 mg/d of a CoQ10supplement. Results The elevated creatine kinase and lactate levels with abnormal urine organic acid and acylcarnitine profiles in this patient suggested a mitochondrial disorder. Skeletal muscle histochemical evaluation revealed ragged red fibers, and respiratory chain enzyme analyses showed partial reductions in complex I, I + III, and II + III activities with greater than 200% of normal citrate synthase activity. The CoQ10concentration in skeletal muscle was 46% of the normal reference mean. The in vitro addition of 50 μmol/L of coenzyme Q1to the succinate cytochrome-creductase assay of the patient’s skeletal muscle whole homogenate increased the succinate cytochrome-creductase activity 8-fold compared with 2.8-fold in the normal control homogenates. Follow-up of the patient in 6 months demonstrated significant clinical improvement with normalization of creatine kinase and lactate levels. Conclusions The absence of central nervous system involvement and recurrent myoglobinuria expands the clinical phenotype of this treatable mitochondrial disorder. The complete recovery of myopathy with exogenous CoQ10supplementation observed in this patient highlights the importance of early identification and treatment of this genetic disorder.

1 November 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
SLSeema R. Lalani
Seema R. Lalani
JZJing Zhang
Jing Zhang
CSChristian P. Schaaf
Christian P. Schaaf
CBChester W. Brown
Chester W. Brown
PMPilar Magoulas
Pilar Magoulas
FXFan Xia
Fan Xia

1 August 2014 in European Journal of Medical Genetics
Verified
Journal Article
Closed access
SLSeema R. Lalani
Seema R. Lalani
JBJohn W. Belmont
John W. Belmont

21 September 2011 in Genome Biology
Verified
Journal Article
Open access
PDF file
MTMuhammad Tariq
Muhammad Tariq
JBJohn W. Belmont
John W. Belmont
SLSeema Lalani
Seema Lalani
TSTeresa Smolarek
Teresa Smolarek
SWStephanie M Ware
Stephanie M Ware
Background: Heterotaxy-spectrum cardiovascular disorders are challenging for traditional genetic analyses because of clinical and genetic heterogeneity, variable expressivity, and non-penetrance. In this study, high-resolution SNP genotyping and exon-targeted array comparative genomic hybridization platforms were coupled to whole-exome sequencing to identify a novel disease candidate gene. Results: SNP genotyping identified absence-of-heterozygosity regions in the heterotaxy proband on chromosomes 1, 4, 7, 13, 15, 18, consistent with parental consanguinity. Subsequently, whole-exome sequencing of the proband identified 26,065 coding variants, including 18 non-synonymous homozygous changes not present in dbSNP132 or 1000 Genomes. Of these 18, only 4 - one each in CXCL2, SHROOM3, CTSO, RXFP1 - were mapped to the absence-of-heterozygosity regions, each of which was flanked by more than 50 homozygous SNPs, confirming recessive segregation of mutant alleles. Sanger sequencing confirmed the SHROOM3 homozygous missense mutation and it was predicted as pathogenic by four bioinformatic tools. SHROOM3 has been identified as a central regulator of morphogenetic cell shape changes necessary for organogenesis and can physically bind ROCK2, a rho kinase protein required for left-right patterning. Screening 96 sporadic heterotaxy patients identified four additional patients with rare variants in SHROOM3. Conclusions: Using whole exome sequencing, we identify a recessive missense mutation in SHROOM3 associated with heterotaxy syndrome and identify rare variants in subsequent screening of a heterotaxy cohort, suggesting SHROOM3 as a novel target for the control of left-right patterning. This study reveals the value of SNP genotyping coupled with high-throughput sequencing for identification of high yield candidates for rare disorders with genetic and phenotypic heterogeneity.